Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

Zhang Liang; Wang Xiaoen; Bullock Andrea J.; Callea Marcella; Shah Harleen; Song Jiaxi; Moreno Kelli; Visentin Barbara; Deutschman Douglas; Alsop David C.; Atkins Michael B.; Mier JamesW.; Signoretti Sabina; Bhasin Manoj; Sabbadini Roger A.; Bhatt Rupal S.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

【24h】

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

机译：抗S1P抗体作为VEGFR TKI抗性肾癌的新型治疗策略

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell carcinoma (RCC). However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for patients with TKI-naive or -resistant RCC.

机译：目的：VEGFR2酪氨酸激酶抑制（TKI）是转移性肾细胞癌（RCC）患者的一种有价值的治疗方法。但是，对治疗的抵抗力是不可避免的。鉴定新靶标可为未接受TKI或耐药的RCC患者提供更好的治疗。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2015年第8期|共10页
作者
Zhang Liang; Wang Xiaoen; Bullock Andrea J.; Callea Marcella; Shah Harleen; Song Jiaxi; Moreno Kelli; Visentin Barbara; Deutschman Douglas; Alsop David C.; Atkins Michael B.; Mier JamesW.; Signoretti Sabina; Bhasin Manoj; Sabbadini Roger A.; Bhatt Rupal S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer [J] . Zhang Liang, Wang Xiaoen, Bullock Andrea J., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第8期

机译：抗S1P抗体作为VEGFR TKI抗性肾癌的新型治疗策略
2. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. [J] . Journal of gastroenterology . 2009,第9期

机译：抗CD9抗体在胃癌中的新型治疗策略。
3. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers [J] . Taisei Nakamoto, Yoko Murayama, Kenji Oritani, Journal of Gastroenterology . 2009,第9期

机译：抗CD9抗体治疗胃癌的新策略
4. Cancer Immunotherapy Based on Engineered Novel Antibodies to Treat Cancers and Build Better Therapeutics [C] . Yanling Wu, Tianlei Ying PEGS . 2016

机译：基于工程新颖的抗体治疗癌症的癌症免疫疗法，并构建更好的治疗方法
5. Using the allergic immune system to target cancer: Tumor specific IgE antibodies as cancer therapeutics [D] . Teo, Zhao Ying Pearline 2008

机译：使用过敏性免疫系统靶向癌症：肿瘤特异性IgE抗体可作为癌症治疗剂
6. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer [O] . Liang Zhang, Xiaoen Wang, Andrea J. Bullock, -1

机译：抗S1P抗体作为VEGFR TKI耐药性肾癌的新型治疗策略
7. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer [O] . Han Xie, Vladimir A. Valera, Maria J. Merino, 2009

机译：LDH-一种抑制作用，治疗遗传性裂纹症和肾细胞癌的治疗策略
8. Development of Anti-GLUT-1 Antibody as a Novel Therapeutic Strategy Against Breast Cancer [R] . Simon, G. R., Banerjee, S. 2008

机译：开发抗GLUT-1抗体作为一种新的抗乳腺癌治疗策略

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

摘要

著录项

相似文献

相关主题

期刊订阅